PITTSBURGH — Generic drug maker Mylan's board of directors has approved a new management structure for the company, effective Jan. 1, 2012.
Mylan's board approved the transition of current chairman and CEO Robert Coury to the new role of executive board chairman. With this, Mylan president Heather Bresch will become CEO and directly report to the company's board.
Replacing Bresch as president is Mylan COO Rajiv Malik, while the generic drug maker's current president of North America operations, Harry "Hal" Korman, will be promoted to COO. Replacing Korman will be Tony Mauro. Mauro, who serves as president of Mylan Pharmaceuticals, will retain his current role in addition to his new role as president of North America operations.
Coury, Bresch, Malik, Korman and Mauro have agreed to new, 3-year contracts in conjunction with these leadership changes, Mylan said.